Drug DevelopmentIMG-007 has shown comparable efficacy to other OX40 therapies in development in atopic dermatitis, with a more favorable safety profile due to its non–T-cell-depleting design.
Market OpportunityThere is a blockbuster opportunity for IMG-007 in atopic dermatitis and longer-term potential in additional inflammatory and immunological indications.
MergerThe merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.